Discovery of Bispecific T-Cell Engagers Targeting Covalent Drug-Modified KRASG12C Neoantigens
Time: 2:15 pm
day: Day Two
Details:
- Development of engineered bispecific T-Cell engagers that recognize KRAS covalent inhibitor–modified peptide-MHC complexes with high affinity and specificity
- Companion immunotherapy approach designed to complement KRASG12C inhibitors enabling selective killing of resistant tumor cells in vitro and in vivo
- Cross-HLA binding and structural insights supporting broad patient coverage and the molecular basis for recognition of hapten-modified targets
